Publications by authors named "Daisuke Horio"
Article Synopsis
- Malignant pleural mesothelioma (MPM), a deadly cancer linked to asbestos, has seen limited effective treatments, but combining ipilimumab and nivolumab shows promise for better patient outcomes.
- Researchers evaluated whether nintedanib, an antiangiogenic drug, could enhance the effects of the anti-PD-1 antibody; while it wasn't effective in stopping cell growth in lab tests, it significantly reduced tumor growth in mouse models.
- Nintedanib was found to decrease tumor-associated macrophages that promote tumor growth, while also altering their function, and when combined with anti-PD-1 therapy, it helped reactivate the immune response against mesothelioma cells.
Malignant pleural mesothelioma (MPM) is an asbestos-related aggressive malignant neoplasm. Due to the difficulty of achieving curative surgical resection in most patients with MPM, a combination chemotherapy of cisplatin and pemetrexed has been the only approved regimen proven to improve the prognosis of MPM. However, the median overall survival time is at most 12 mo even with this regimen.
View Article and Find Full Text PDFSmall-cell lung cancer (SCLC) is characterized by one of neuroendocrine tumors, and is a clinically aggressive cancer due to its rapid growth, early dissemination, and rapid acquisition of multidrug resistance to chemotherapy. Moreover, the standard chemotherapeutic regimen in SCLC has not changed for three decades despite of the dramatic therapeutic improvement in non-SCLC. The development of a novel therapeutic strategy for SCLC has become a pressing issue.
View Article and Find Full Text PDFPulmonary pleomorphic carcinoma (PPC) has a poor prognosis due to the poor results of treatment with systemic chemotherapy. We report the case of a 73-year-old woman with PPC who showed a favorable response to nivolumab. As first-line treatment for postoperative recurrence, she received carboplatin and nanoparticle albumin-bound paclitaxel.
View Article and Find Full Text PDF